ÂÜÀòÂÒÂ×

Mark Lalli has a diverse work experience spanning from 2009 to 2022. Mark began their career as a Research Assistant at the University of Massachusetts Lowell, where they researched electrical properties conducting polymers and developed biological and chemical sensors. In 2012, they moved to Northeastern University, where they were a Research Assistant, Teaching Assistant, and Teaching Assistant. In 2015, they joined Obz Design as a Product Development Engineer, where they developed an algorithm to calculate blood hemoglobin levels, prototyped a novel medical device, and designed a clinical experimental protocol. In 2017, they began working at MilliporeSigma as an Engineer III - Cell Therapy Bioprocessing, where they invented a novel centrifugal downstream processing device and developed an operable cell retention filter. In 2019, they joined Sigilon Therapeutics, Inc. as an Associate Director, Process Development, where they led a team of scientists to streamline manufacture of core programs, developed protocols for cGMP manufacture of cellular drug substance and drug product, and supported regulatory filings and amendments. Mark also worked at ImmunoGen, Inc. as a Senior Development Engineer, where they developed control strategies and processing methods for continuous antibody-drug conjugate (ADC) manufacture and optimized countercurrent tangential flow diafiltration for ADC formulation. Currently, they are employed at Be Biopharma as an Associate Director, Process Development.

Mark Lalli earned a Doctor of Philosophy (Ph.D.) in Chemical Engineering from Northeastern University in 2016. Prior to this, they earned a BSE in Chemical Engineering and Nanomaterials Engineering from the University of Massachusetts Lowell in 2012.